```html

X‑linked Chronic Granulomatous Disease (CGD) Fever

What is X‑linked chronic granulomatous disease fever?

Chronic Granulomatous Disease (CGD) is a rare inherited immunodeficiency in which phagocytes (a type of white blood cell) cannot produce the reactive oxygen species needed to kill certain bacteria and fungi. The X‑linked form accounts for about 65–70 % of cases and is caused by mutations in the CXCR1 (formerly CYBB) gene that encodes the gp91^phox protein, a critical component of the NADPH oxidase complex.

Because the immune system cannot efficiently destroy invading microbes, people with X‑linked CGD are prone to recurrent infections and to chronic inflammatory “granulomas” (clusters of immune cells). Fever is one of the most common presenting signs and often signals an acute infection, an inflammatory flare, or a complication such as an abscess. The fever may be low‑grade and persistent, or high‑grade and sudden, depending on the underlying trigger.

Understanding the cause of fever in CGD is essential because infections can progress rapidly and may require aggressive antimicrobial therapy or even surgical drainage.

Common Causes

Fever in a patient with X‑linked CGD can stem from a variety of infectious and non‑infectious processes. The most frequent precipitants include:

• Staphylococcus aureus skin and soft‑tissue infections – often produce abscesses that become febrile.
<
• Burkholderia cepacia complex – a Gram‑negative rod that is notoriously difficult to treat.
• Aspergillus species (especially A. fumigatus) – invasive pulmonary or sinus disease can cause persistent fever.
• Serratia marcescens – another Gram‑negative bacterium that frequently causes bacteremia in CGD.
• Nocardia spp. – filamentous bacteria that cause pulmonary or cutaneous infections.
• Mycobacterium avium complex (MAC) – especially in older children and adults.
• Fungal infections other than Aspergillus – such as Candida, Histoplasma, or Coccidioides.
• Granulomatous inflammation without an active pathogen – can produce fever spikes (e.g., gastrointestinal granulomas mimicking Crohn’s disease).
• Vaccination reactions – live‑attenuated vaccines (e.g., BCG) can cause disseminated disease in CGD.
• Autoimmune or inflammatory flare – CGD patients may develop inflammatory arthritis or colitis that triggers fever.

Associated Symptoms

Fever in CGD rarely occurs in isolation. The following symptoms often accompany a febrile episode and can help clinicians pinpoint the underlying cause:

• Localized pain, swelling, or redness → suggests abscess or cellulitis.
• Cough, shortness of breath, or pleuritic chest pain → points to pulmonary infection (often Aspergillus or Nocardia).
• Persistent diarrhea, abdominal cramping, or weight loss → may indicate gastrointestinal granulomas or infection.
• Headache, photophobia, neck stiffness → warning of central nervous system involvement (rare but possible with Listeria or fungal meningitis).
• Night sweats and unexplained weight loss → signs of chronic infection such as MAC or tuberculosis.
• Fatigue, malaise, and poor appetite → common systemic responses to infection.
• Skin lesions (pustules, papules, nodules) → cutaneous staphylococcal or fungal infection.
• Joint pain or swelling → inflammatory arthritis associated with CGD granulomas.

When to See a Doctor

People with X‑linked CGD should have a low threshold for seeking medical attention because infections can rapidly become life‑threatening. Immediate evaluation is warranted if any of the following occur:

• Fever ≥ 38.5 °C (101.3 °F) lasting more than 24 hours.
• Rapidly worsening pain, swelling, or redness at any site.
• Shortness of breath, chest pain, or a new cough.
• Persistent vomiting, severe diarrhea, or blood in stool.
• Neurological changes (confusion, severe headache, seizures).
• Unexplained rash that spreads or becomes necrotic.
• Any sign of sepsis – such as hypotension, rapid heart rate, or mental status change.

Even if symptoms seem mild, contacting the primary immunology or infectious‑disease team is advisable because early initiation of appropriate antibiotics can prevent complications.

Diagnosis

Diagnosing the cause of fever in an X‑linked CGD patient involves a systematic approach that combines clinical assessment, laboratory testing, and imaging.

1. Clinical Evaluation

• Detailed history – recent exposures, travel, vaccination status, and prior infection patterns.
• Physical exam – looking for focal signs of infection (e.g., abscess, lung crackles, abdominal tenderness).

2. Laboratory Studies

• Complete blood count (CBC) with differential – often shows neutrophilia or, paradoxically, neutropenia in severe infection.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are usually elevated.
• Blood cultures – at least two sets drawn before antibiotics.
• Targeted cultures – from wound swabs, sputum, urine, or cerebrospinal fluid as indicated.
• Fungal biomarkers – serum galactomannan and β‑D‑glucan for Aspergillus and other fungi.
• Serology/PCR – for atypical organisms (e.g., Mycobacterium, Nocardia).

3. Imaging

• Chest X‑ray or CT scan – to detect pneumonia, fungal nodules, or mediastinal abscesses.
• Ultrasound – useful for evaluating superficial abscesses, liver/spleen lesions.
• MRI – preferred for central nervous system or deep musculoskeletal infections.

4. Specialized Tests for CGD Confirmation (if not already known)

• Dihydrorhodamine (DHR) flow cytometry assay – gold standard for assessing NADPH oxidase activity.
• Genetic testing – identifies the specific CXCR1 mutation.

All investigations should be performed promptly; in many centers, a “fever bundle” protocol is activated for CGD patients to expedite diagnosis.

Treatment Options

Treatment aims to eradicate the infection, control inflammation, and support the patient’s immune function. Management is individualized based on the identified pathogen and disease severity.

1. Empiric Antimicrobial Therapy

Because CGD patients are at risk for a broad range of organisms, empiric regimens often cover Gram‑positive, Gram‑negative, and fungal pathogens until culture results guide narrowing:

• Antibiotics – Intravenous (IV) vancomycin plus a broad‑spectrum β‑lactam (e.g., cefepime or meropenem) is a common starting point.
• Anti‑fungal agents – Voriconazole or posaconazole for suspected Aspergillus; amphotericin B may be used for severe disease.
• Adjunctive coverage – Trimethoprim‑sulfamethoxazole (TMP‑SMX) for Burkholderia and Nocardia; azithromycin for MAC if indicated.

Therapy is usually continued for 2–4 weeks for uncomplicated infections, longer for deep or osteomyelitic disease.

2. Targeted Therapy

Once the pathogen is identified, antibiotics are de‑escalated to the most effective, narrow‑spectrum agents to reduce toxicity and resistance.

3. Surgical Intervention

• Drainage of abscesses (percutaneous or operative).
• Debridement of necrotic tissue.
• Resection of infected bone or lung tissue in refractory cases.

4. Anti‑inflammatory Management

Granulomatous inflammation may require short courses of corticosteroids (e.g., prednisone 1 mg/kg/day tapered over weeks) or steroid‑sparing agents such as azathioprine or infliximab, especially for colitis or arthritis. Close coordination with an immunologist is essential.

5. Prophylactic Measures (Long‑term)

• Antimicrobial prophylaxis – Lifelong TMP‑SMX (once daily) to prevent bacterial and Pneumocystis infections.
• Antifungal prophylaxis – Itraconazole or posaconazole in patients with history of mold infection.
• Vaccinations – Inactivated vaccines are safe; live vaccines are generally avoided.

6. Home‑Based Support

• Maintain adequate hydration and nutrition.
• Use acetaminophen or ibuprofen for fever control, but avoid NSAIDs if renal function is compromised.
• Monitor temperature at least twice daily and keep a symptom diary.
• Educate caregivers on wound care and early signs of infection.

Prevention Tips

While the underlying genetic defect cannot be reversed, several strategies can reduce the frequency and severity of febrile episodes:

• Adherence to prophylactic antibiotics/antifungals as prescribed.
• Good hand hygiene – wash hands with soap for 20 seconds, especially after outdoor activities.
• Avoidance of high‑risk exposures – soil, stagnant water, bird droppings, and construction dust are common sources of Burkholderia and fungi.
• Prompt wound care – clean any cuts or abrasions immediately; use antiseptic and seek medical review for deep wounds.
• Regular follow‑up with an immunology specialist to adjust prophylaxis and monitor lung function.
• Vaccination updates – receive inactivated influenza, pneumococcal, and COVID‑19 vaccines.
• Environmental controls – use HEPA filters at home if mold exposure is a concern; avoid indoor plant soil.
• Genetic counseling for families planning future pregnancies.

Emergency Warning Signs

Key Take‑aways

• X‑linked CGD is a genetic defect that impairs the killing ability of phagocytes, making fever a red flag for infection.
• Common culprits include Staphylococcus aureus, Burkholderia, Aspergillus, Serratia, Nocardia, and MAC.
• Associated symptoms such as localized pain, cough, or gastrointestinal upset help narrow the source.
• Prompt medical evaluation, blood cultures, and imaging are essential; empiric broad‑spectrum antibiotics plus antifungals are standard while awaiting results.
• Long‑term prophylaxis, vigilant hygiene, and avoidance of high‑risk environments reduce recurrence.
• Any sign of sepsis, severe respiratory distress, or neurologic change constitutes an emergency.

---

References:

1. Mayo Clinic. Chronic granulomatous disease. https://www.mayoclinic.org. Accessed May 2026.
2. National Institutes of Health, Genetics Home Reference. CGD – X‑linked. https://ghr.nlm.nih.gov.
3. Cleveland Clinic. Chronic granulomatous disease – treatment & management. https://my.clevelandclinic.org.
4. American Academy of Pediatrics. Immunodeficiency infections in children. Pediatrics. 2023;152(5):e20221230.
5. World Health Organization. Guidelines for the prevention and treatment of opportunistic infections in immunocompromised hosts. WHO Press; 2022.
6. Seger RA, et al. Management of infections in chronic granulomatous disease. J Clin Immunol. 2021;41(7):1326‑1342.

```